KMT2A and acute lymphoblastic leukemia: Given that kinases represent the largest group of druggable targets in the human genome [19], and that KMT2A-r ALL is an epigenetically driven malignancy, combinations of epigenetic-based drugs and kinase inhibitors may well represent effective treatments for this elusive type of leukemia.